2- fluorodeoxyglucose

Retention, too, is highly tissue-specific. Sometimes, the extraction mechanism is also the retention mechanism, as for Tc-sestamibi, which is retained in mitochondria as long as transmembrane potentials remain intact. Others are separate. F-2-Fluorodeoxyglucose enters the cell by the same pathway as glucose, but is trapped because it is not a substrate for hexokinase, preventing further intracellular metabohsm. 

Dozens of compounds have been used in in vivo fluonne NMR and MRI studies, chosen more for their commercial availability and established biochemistry than for ease of fluonne signal detection [244] Among the more common of these are halothane and other fluormated anesthetics [245, 246], fluorodeoxyglucose [242 243], and perfluormated synthetic blood substitutes, such as Fluosol [246], a mixture of perfluorotnpropylamine and perfluorodecahn Results have been Imut-ed by chemical shift effects (multiple signals spread over a wide spectral range) and long acquisition times... 

PET scans with 18F-fluorodeoxyglucose (18F-FDG) have an established role in the localization of epileptic foci in patients being evaluated for epilepsy surgery. 

The main radiopharmaceuticals labelled with fluorine-18, routinely prepared ([2-i F] fluorodeoxyglucose [ F]FDG [26-28], [i F]fluoro-L-DOPA [29], [i F]altanserin [30, 31], [ F]setoperone [32]) are presented with their uses in Table 2. For comparison, the most common tracers labelled with carbon-11 (methionine [33], palmitic acid [34], flumazenil (RO 15.1788) [35], PK 11195 [36], raclopride [37], deprenyl [38], Way-100635 [39], McN-5652Z [40], CGP 12177 [41]) are shown in Table 3. By far, [ F]FDG is the most widely studied, particularly in oncology for the diagnosis of tumours, detection of sub-clinical diseases, assessment of therapy responses, and detection of recurrence. F-Steroids [42], F-proteins or peptides, or F-labelled tissue specific agents have also been synthesized for the detection and monitoring of various malignancies [43]. 

F]p2 addition on the double bond of triacetoxyglucal [26], followed by deprotection of the acetate functions (Scheme 5), was the first method used to produce [2- F]fluorodeoxyglucose. About 10% of [ F]fluorodeoxymannose (FDM) were also formed in the reaction (Scheme 5). 

Gropler RJ, Geltman EM, Sampathkumaran K, Perez JE, Schechtman KB, Conversano A et al. Comparison of carbon-11-acetate with fluorine-18-fluorodeoxyglucose for delineating viable myocardium by positron emission tomography. J Am Coll Cardiol 1993 22 1587-1597... 

Bax JJ, Cornel JH, Visser FC, Fioretti PM, van LA, Reijs AE et al. Prediction of recovery of myocardial dysfunction after revascularization. Comparison of fluorine-18 fluorodeoxyglucose/thalhum-201 SPECT, thaUium-201 stress-reinjection SPECT and dobutamine echocardiography. J Am Coll Cardiol 1996 28 558-564... 

Bonow RO, Dilsizian V, Cuocolo A, Bacharach SL. Identification of viable myocardium in patients with chronic coronary artery disease and left ventricular dysfunction. Comparison of thallium scintigraphy with reinjection and PET imaging with 18F-fluorodeoxyglucose. Circulation 1991 83 26-37... 

Dilsizian V, Arrighi JA, Diodati JG, Quyyumi AA, Alavi K, Bacharach SL et al. Myocardial viability in patients with chronic coronary artery disease. Comparison of 99mTc-sestamibi with thallium reinjection and [18F]-fluorodeoxyglucose. Circulation 1994 89 578-587... 

C.S. Brock, S.R. Meikle, P. Price, Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumors benefit oncology Eur. J. Nucl. Med. 24 (1997) 691-705. 

M. Tatsumi, C. Cohade, Y. Nakamoto, R.L. Wahl, Fluorodeoxyglucose uptake in the aortic wall at PET/CT Possible finding for active atherosclerosis. Radiology 229 (2003) 831-837. 

ATawakol, R.Q. Migrino, U. Hoffmann, S Abbara, S Houser, H Gewirtz, J.E. Muller, T.J Brady, A.J Fischman, Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography, J. Nucl. Cardiol. 12 (2005) 294-301. 

J.H.F. Rudd, K.S. Myers, S. Bansilal, J. Machac, A. Rafique, M. Farkouh, V. Fuster, Z.A. Fayad, Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible Implications for atherosclerosis therapy trials, J. Am. Coll. Cardiol. 50 (2007) 892-896. 

N. Tahara, H. Kai, M. Ishibashi, H. Nakaura, H. Kaida, K. Baba, N. Hayabuchi, T. Imaizumi, Simvastatin attenuates plaque inflammation Evaluation by fluorodeoxyglucose positron emission tomography, J. Am. Coll. Cardiol 48 (2006) 1825-1831. 

M. Dietlein, W. Weber, M. Schwaiger, H. Schicha, F-Fluorodeoxyglucose positron emission tomography in restaging of colorectal cancer, Nuklearmedizin 42(4) (2003) 145-156. 

M. Mukai, S. Sadahiro, S. Yasuda, H. Ishida, N. Tokunaga, T. Tajima, H. Makuuchi, Preoperative evaluation by whole-body F-fluorodeoxyglucose positron emission tomography in patients with primary colorectal cancer, Oncol. Rep. 7(1) (2000) 85-87. 

L. Staib, H. Schirrmeister, S.N. Reske, H.G. Beger, Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making. Am. J. Surg. 180(1) (2000) 1-5. 

F. H. Corstens, W.J. Oyen, Value of positron emission tomography with [F-18] fluorodeoxyglucose in patients with colorectal liver metastases A prospective study, J. Clin. Oncol. 20(2) (2002) 388-395. 

H.L. van Westreenen, M. Westerterp, P.M. Bossuyt, J. Pruim, G.W. Sloof, J.J. van Lanschot, H. Groen, J.T. Plukker, Systematic review of the staging performance of F-fluorodeoxyglucose positron emission tomography in esophageal cancer, J. Clin. Oncol. 22(18) (2004) 3805-3812. 

R.J. Downey, T. Akhurst, M. Gonen, A. Vincent, M.S. Bains, S. Larson, V. Rusch, Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection, J. Clin. Oncol. 22(16) (2004) 3255-3260. 

S.G. Stroobants, I. D Hoore, C. Dooms, P.R. De Leyn, P.J. Dupont, W.W. De, G. T. De, J.A. Verschakelen, L.A. Mortelmans, J.F. Vansteenkiste, Additional value of whole-body fluorodeoxyglucose positron emission tomography in the detection of distant metastases of non-small-cell lung cancer, Clin. Lung Cancer 4(4) (2003) 242-247. 

F. Janicke, H. Graeff, M. Schwaiger, Positron emission tomography using [(18)F] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer, J. Clin. Oncol. 18(8) (2000) 1689-1695. 

R. Kubota, K. Kubota, S. Yamada, M. Tada, T. Ido, N. Tamahashi, Microautoradio-graphic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake, J. Nucl. Med. 35(1) (1994) 104-112. 

S. Stanzei, B. Asadpour, K. Hamacher, H.H. Coenen, U. Buell, M.J. Eble, [ F] fluoromisonidazole and [ F] fluorodeoxyglucose positron emission tomography in response evaiuation after chemo-/radiotherapy of non-small-cell lung cancer A feasibility study, BMC Cancer 6 (2006) 51. 

O. Kobori, Y. Kirihara, N. Kosaka, T. Hara, Positron emission tomography of esophageal carcinoma using (11)C-choline and (18)F-fluorodeoxyglucose A novel method of preoperative lymph node staging. Cancer 86(9) (1999) 1638-1648. 

D.T. Price, R.E. Coleman, R.P. Liao, C.N. Robertson, T.J. Polascik, T.R. DeGrado, Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer, J. Urol. 168(1) (2002) 273-280. 

W. Langsteger, M. Heinisch, I. Fogelman, The role of fluorodeoxyglucose, F-dihydroxyphenylalanine, F-choline, and F-fluoride in bone imaging with emphasis on prostate and breast, Semin. Nucl. Med. 36(1) (2006) 73-92. 

---